神经生物学生物标记市场（按生物标记类型、技术平台、应用和最终用户）—2025-2032 年全球预测

预计到 2032 年神经生物学标记物市场将成长至 301.5 亿美元，复合年增长率为 14.45%。

主要市场统计数据
基准年2024年	102.4亿美元
预计2025年	117.4亿美元
预测年份：2032年	301.5亿美元
复合年增长率（%）	14.45%

神经生物标誌物的权威介绍，阐述科学进步、临床效用、商业化路径以及对相关人员的策略意义

神经系统生物标记正在改变临床医生和科学家处理复杂中枢神经系统疾病的方式，使其从概念性目标转变为临床开发、诊断工作流程和转化研究中的可操作要素。这些可测量的生物指标涵盖分子特征、成像模式和功能读数，两者结合，可实现早期检测、精细的患者分层以及对治疗反应的客观监测。因此，临床、商业和监管相关人员越来越多地将生物标记视为降低临床试验变异性和提高药物开发信噪比的重要工具。

检测灵敏度、计算分析和高解析度成像方面的进步正在加速候选标记物向经验证的临床应用的转化。互补的驱动力包括：对精准神经病学的日益关注、支付方对循证诊断的兴趣，以及学术联盟与产业日益深化的合作。这些力量共同重塑了开发路径、投资重点和应用曲线，为寻求引领生物标记解决方案的公司创造了机会和商业挑战。本介绍描绘了一幅更广阔的图景，强调了科学与商业化之间的相互关係，并展望了生物标记物将如何影响研究和临床护理领域的策略决策。

积极整合技术、监管环境和护理服务方面的变化，重新定义神经生物标记格局和价值链

随着技术的融合、监管环境的日益成熟以及护理模式的不断发展，神经系统生物标记领域正在发生变化。高通量分子平台如今正与多模态成像和高精度蛋白质体学相辅相成，使疾病表征的精细度达到了前所未有的水平。同时，先进的机器学习和联合分析等计算方法正在从异质资料集中提取临床可操作的讯号，加快生物标记检验週期，并实现自适应试验设计。

法律规范满足了对强有力证据标准的需求，同时为合格的生物标记和伴随诊断提供了简化的途径。支付者和医疗系统更加重视诊断价值和长期健康经济效益，并激励那些能够显着改变患者管理或降低下游成本的生物标记。此外，透过远端监控和数位终端实现临床研究的去中心化，拓宽了生物标记收集和应用的范围，技术供应商、学术中心和临床网路之间的合作在扩大证据产生方面发挥核心奖励。总而言之，这些转变正在将生物标记从孤立的研究产品转变为治疗生态系统的整合组成部分，影响着开发时间表、资金配置和跨部门合作。

2025 年美国关税对整个生物标记生态系统的采购、创新途径和业务连续性的累积影响的策略分析

2025年美国关税对整个神经生物标记生态系统的供应链、筹资策略和成本结构产生了复合影响。依赖进口的领域，例如高阶成像硬体和专用检测试剂，面临直接的价格压力，迫使研究机构和临床实验室重新评估资本采购计画和消耗品库存。这些发展趋势强化了库存管理、合约重新谈判以及早期供应商多元化对于依赖进口设备和单一来源试剂的研究机构的重要性。

累积的后果不仅影响了直接采购成本，也影响了计划优先顺序和营运顺序。拥有强大国内製造伙伴关係和垂直整合供应链的组织能够缓解短期中断，并维持关键研究的连续性。相反，规模较小的研究机构和一些委外研发机构面临采购延迟，影响了註册时间和分析吞吐量。为此，相关人员加快了本地化供应的步伐，包括技术转移协议、与国内製造商的共同开发契约以及为供应商提供确定性的长期采购合约。

重要的是，这种政策环境也引发了不同技术领域的策略性再平衡。资本密集型影像处理平台通常需要集中投资和签订专业服务合同，因此采购週期更长，且对总拥有成本 (TCO) 的考虑也更高。相反，进口依赖程度较低的模组化和分散式技术，例如某些分子平台和可携式诊断工具，由于其相对韧性而吸引了更大的关注。因此，关税引发了策略性采购优化，加速了关键部件的在地化，并重新强调了供应链可视性和情境规划。

细分主导的深入洞察，展示生物标记类别、平台选择、应用和最终用户如何相互作用以形成发展策略和采取路径

细分洞察揭示了微妙的采用模式和技术发展轨蹟的差异，可以帮助开发者、临床医生和投资者确定优先顺序。细胞标记物和蛋白质特征通常从发现阶段过渡到检测方法优化阶段；基因标记物为持续的患者分层提供了机会，尤其是在存在遗传风险或变异引导疗法的情况下；影像生物标记物为疾病进展提供空间和时间背景；代谢物测量可以提供敏感的生化变化指标。每种生物标记物都面临不同的验证挑战、样本处理要求以及与临床工作流程的整合点。

这些生物标记所依赖的技术平台决定了可行性、通量和可解释性。酵素结合免疫吸附检测法等成熟的免疫测量法仍然是蛋白质定量的基础，而质谱法则为蛋白质组学和代谢体学学分析提供了高特异性。次世代定序，包括 RNA 定序、标靶重定序和全基因组定序方法，已发展成为重要的基因研究平台，支持发现和诊断应用。聚合酵素链锁反应继续提供快速灵敏的核酸检测，而电脑断层扫描、功能性近红外线光谱、磁振造影和正子断层扫描等成像技术则提供解剖和功能表型分析，这通常对于分子观察的背景分析至关重要。

应用涵盖诊断、药物开发、纵向监测、预后建模和基础研究，每种应用都有不同的性能标准和监管要求。最终用户包括：促进大规模研究和检测验证的受託研究机构、将标记物转化为临床报告的诊断实验室、在护理点应用生物标记物的医院和诊所、采用标记物降低开发项目风险的製药和生物技术公司，以及推动发现和早期验证的研究机构。了解每个细分轴如何相互作用，对于制定切合实际的产品蓝图和伙伴关係策略至关重要。

全面的区域概述，介绍美洲、欧洲、中东和非洲以及亚太地区的结构、监管和投资差异如何影响生物标记开发和商业化结果

区域动态对神经系统生物标记的监管途径、投资流和应用曲线有显着的影响，不同地区的优势和挑战也各不相同。在美洲，成熟的研究基础设施、创投和公共资金筹措管道以及主要的临床试验网络正在加速转化医学的发展。该地区集中了专业的研究中心，并以支付主导，强调临床效用的证明，这促进了诊断技术和伴随标誌物的快速试点应用，同时也吸引了能够将有前景的技术推广到多中心研究的伙伴关係。

欧洲、中东和非洲地区拥有复杂的管理体制和医疗保健服务模式，这些都影响着生物标记的部署。儘管中东和非洲市场的基础设施成熟度参差不齐，但精准医疗能力的投资正在迅速成长。在全部区域，协调工作和协作平台对于实现数据共用和建立可互通的生物标誌物鑑定标准正变得越来越重要。

在亚太地区，快速发展的临床研究能力、公共和私人领域对生物技术的大量投资以及庞大的患者群体，为可扩展的检验和真实世界数据生成提供了重要机会。该地区的多个市场正在积极投资本地製造和数位健康平台，这可以加速分散式生物标记部署，并实现创新的临床实验设计。这些区域特征的结合可以为场地选择、伙伴关係模式和监管参与等方面的策略选择提供参考，从而优化证据生成和商业化路径。

深入研究平台领导、策略伙伴关係、监管参与和商业化模式如何决定生物标记生态系统中公司之间的竞争定位

公司层级的动态凸显出这样一种格局：技术领先、策略伙伴关係和平台广度决定了竞争地位。仪器製造商和平台提供者透过精度、扩充性和与分析生态系统的整合来实现差异化，而试剂和耗材供应商则注重批次间一致性、供应链可靠性和检测标准化。诊断开发人员专注于临床验证和付款人参与，以将分析性能转化为临床应用；製药公司也越来越多地将生物标记纳入研究设计中，以支持标靶治疗并优化患者选择。

公司、学术中心和临床网路之间的策略合作正在不断推进，以实现对生物样本库、纵向队列和检验终点的共用存取。有些公司追求垂直整合以控制价值链中的关键点，而有些公司则优先考虑开放平台和资料互通性，以加速合作伙伴的吸收。在整个生态系统中，竞争差异化是透过投资监管科学来降低核准途径风险，建立强大的真实世界证据项目来证明临床效用，以及部署将诊断报销与已证实的健康结果相结合的商业模式来实现的。随着生物标誌物从研究工具转向常规临床应用，这些公司层级的策略共同影响谁能获得价值。

为领导者提供清晰、实用的建议，以建立供应弹性、加速验证、儘早与监管机构接触，并透过永续的经营模式将生物标誌物商业化

产业领导者应采取多管齐下的策略，在短期业务韧性与长期技术领先之间取得平衡。首先，透过供应商多元化、本地製造伙伴关係和长期采购协议来增强供应链韧性，将降低贸易中断和成本波动的风险。其次，投资分析基础设施和管理纵向资料集，将增强异质人群中生物标记检验的能力，并支持付款人就临床效用和价值进行对话。

研发领导者还应优先在研发早期与监管机构合作，以确保证据策略与资格认证路径一致，并促进临床应用。组成竞争前验证联盟并参与标准化计划可以扩大认可并减少重复工作。从商业性角度来看，设计灵活的经营模式（从付费检验到基于结果的报销试点）可以加速市场准入，同时与付款人和医疗保健提供者共用研发风险。最后，培养一支融合分子科学、影像分析、监管事务和卫生经济学的多学科人才队伍，对于将技术创新转化为持续的临床影响至关重要。这些步骤共同构成了将科学进步转化为可扩展的临床解决方案和永续商业成果的可行蓝图。

透明的混合方法调查方法结合了系统性的次要研究、一手专家访谈和严格的资料三角测量，确保了可靠且检验的见解

研究途径将系统性的二手资料研究与一手相关人员、检验主任、临床试验协调员和供应链高管进行结构化访谈，以了解现实世界的限制因素、应用驱动因素和营运权衡。

我们进行了资料三角检验，以协调资讯来源差异，并揭示在关键问题（例如检测标准化、监管途径和商业化障碍）上的共识和分歧。品管程序包括访谈记录的双盲检验、技术规范的交叉引用以及独立专家对分析假设的检验。调查方法的局限性与新兴生物标记已发表数据的差异性以及区域报告差异有关。这种混合方法设计优先考虑可重复性和可追溯性，同时捕捉可操作决策所需的细微观点。

结论性综合强调了科学进步、营运弹性和共同检验的整合如何实现临床应用和策略价值创造

技术创新、不断演变的法规以及不断变化的商业性奖励，正在促成更精准的诊断和治疗策略。转化医学领域的进展最为强劲，当高保真测量平台与强大的分析框架和协作证据生成模型相结合时，就能产生可用于患者选择、监测和预后的可靠生物标记。同时，供应链薄弱、验证标准差异以及区域监管复杂性等实际障碍，仍在持续影响生物标誌物的采用时间表和策略选择。

那些优先考虑互通性、投资于不同队列验证并建立弹性运作模式的组织将能够更好地将生物标誌物的前景转化为可衡量的临床和商业性成果。透过使产品开发与付款人需求保持一致、积极与监管机构合作以及建立策略伙伴关係关係，相关人员可以充分发挥生物标记在改善患者照护和降低治疗开发风险方面的潜力。这项结论强调，需要采取有计划、协作且资源充足的方法，将科学进步转化为日常临床实践。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 在多中心临床试验中整合血浆磷酸化Tau 217 检测以早期检测阿兹海默症
• 超灵敏单分子阵列技术的出现，可量化血液样本中的神经丝轻链水平
• 开发结合淀粉样β蛋白和Tau异构体的多重脑脊髓液生物标记组用于失智症的鑑别诊断
• 推出免疫检测平台，可远端监测帕金森氏症患者的生物标记变化
• 扩展人工智慧演算法以解释神经退化性疾病早期检测中的复杂生物标记数据模式
• 基于血液的发炎生物标记检测在多发性硬化症治疗试验中追踪小胶质细胞活化的进展
• 扩大监管支持途径，以核准用于药物开发和个人化医疗应用的新型神经生物标记

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章神经生物标记市场（按生物标记类型）

• 蜂巢
• 遗传
• 影像学
• 代谢物
• 蛋白质

9. 神经生物标记市场技术平台

• 酵素结合免疫吸附试验
• 影像技术
  • 电脑断层扫描
  • 功能近红外线光谱
  • 磁振造影
  • 正子断层扫描
• 质谱法
• 次世代定序
  • RNA定序
  • 标靶定序
  • 全基因组定序
• 聚合酵素链锁反应

第 10 章神经生物标记物市场（按应用）

• 诊断
• 药物开发
• 监控
• 预后
• 调查

第 11 章神经生物标记物市场（按最终用户）

• 合约研究组织
• 诊断实验室
• 医院和诊所
• 製药和生物技术公司
• 研究机构

第十二章神经生物标记市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章神经生物标记市场（按类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 神经生物标记市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Quanterix Corporation
  • Meso Scale Diagnostics, LLC
  • Fujirebio Diagnostics, Inc.

The Neurological Biomarkers Market is projected to grow by USD 30.15 billion at a CAGR of 14.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 10.24 billion
Estimated Year [2025]	USD 11.74 billion
Forecast Year [2032]	USD 30.15 billion
CAGR (%)	14.45%

An authoritative introduction to neurological biomarkers that frames scientific advances, clinical utility, commercialization pathways, and strategic implications for stakeholders

Neurological biomarkers have moved from conceptual targets to operational elements in clinical development, diagnostic workflows, and translational research, altering how clinicians and scientists approach complex central nervous system disorders. These measurable biological indicators span molecular signatures, imaging patterns, and functional readouts that together enable earlier detection, refined patient stratification, and objective monitoring of therapeutic response. As a result, stakeholders across clinical, commercial, and regulatory domains increasingly view biomarkers as indispensable tools for reducing trial variability and improving the signal-to-noise ratio in drug development.

Advances in assay sensitivity, computational analytics, and high-resolution imaging have accelerated the translation of candidate markers into validated clinical applications. Complementary drivers include a stronger emphasis on precision neurology, payer interest in evidence-based diagnostics, and deeper collaborations between academic consortia and industry. Taken together, these dynamics are reshaping development pathways, investment priorities, and adoption curves, creating both opportunities and operational challenges for organizations seeking to lead in biomarker-enabled solutions. This introduction frames the broader landscape, clarifies the interplay between science and commercialization, and sets expectations for how biomarkers will influence strategic decision-making across research and clinical care.

A forward-looking synthesis of converging technological, regulatory, and care delivery shifts that are redefining the neurological biomarker landscape and value chain

The landscape for neurological biomarkers is experiencing transformative shifts driven by converging technologies, regulatory maturation, and evolving care models. High-throughput molecular platforms now complement multimodal imaging and high-precision proteomics, enabling a level of granularity in disease characterization that was previously unattainable. At the same time, computational methods such as advanced machine learning and federated analytics are extracting clinically actionable signals from heterogeneous datasets, accelerating biomarker validation cycles and enabling adaptive trial designs.

Regulatory frameworks are responding to the need for robust evidentiary standards while also offering streamlined pathways for qualified biomarkers and companion diagnostics. Payers and health systems are placing greater emphasis on diagnostic value and long-term health economic outcomes, incentivizing biomarkers that demonstrably alter patient management or reduce downstream costs. Additionally, the decentralization of clinical research through remote monitoring and digital endpoints is broadening the contexts in which biomarkers are collected and applied, and partnerships between technology vendors, academic centers, and clinical networks are becoming central to scaling evidence generation. Collectively, these shifts are transforming biomarkers from isolated research outputs into integrated components of therapeutic ecosystems, with implications for development timelines, capital allocation, and cross-sector collaboration.

A strategic analysis of the cumulative implications from United States tariff actions in 2025 on procurement, innovation pathways, and operational continuity across the biomarker ecosystem

Tariff measures introduced in the United States in 2025 have had a compound influence on supply chains, procurement strategies, and cost structures across the neurological biomarker ecosystem. Import-dependent segments such as high-end imaging hardware and specialized assay reagents experienced immediate pricing pressures, prompting research institutions and clinical laboratories to reassess capital procurement timelines and consumables inventories. These dynamics amplified the importance of inventory management, contract renegotiation, and early-stage supplier diversification for organizations that rely on imported instrumentation or single-source reagents.

The cumulative consequences extended beyond direct procurement costs to affect project prioritization and operational cadence. Organizations with robust domestic manufacturing partnerships or vertically integrated supply chains were able to mitigate short-term disruptions and preserve continuity for critical studies. Conversely, smaller research entities and some contract research organizations faced procurement delays that affected enrollment timelines and analytical throughput. In response, stakeholders accelerated initiatives to localize supply, including technology transfer agreements, co-development contracts with domestic manufacturers, and longer-term purchasing commitments that provided certainty to suppliers.

Importantly, the policy environment also triggered strategic rebalancing among technology classes. Capital-intensive imaging platforms, which typically require centralized investments and specialized service contracts, experienced longer procurement cycles and increased total cost of ownership considerations. Conversely, modular and decentralized technologies with lower import dependence, including certain molecular platforms and portable diagnostic tools, garnered elevated interest for their relative resilience. The tariffs therefore acted as a catalyst for strategic procurement optimization, accelerated localization of critical components, and renewed emphasis on supply chain visibility and scenario planning.

Detailed segmentation-driven insights illustrating how biomarker classes, platform choices, applications, and end-users interact to shape development strategies and adoption pathways

Segmentation insights reveal nuanced adoption patterns and differential technology trajectories that inform prioritization for developers, clinicians, and investors. Biomarker types vary in their translational pathways: cellular markers and protein signatures often move from discovery to assay optimization, genetic markers provide durable patient stratification opportunities particularly where heritable risk or variant-guided therapies exist, imaging biomarkers deliver spatial and temporal context for disease progression, and metabolite measures can offer sensitive indicators of biochemical shifts. Each class presents distinct validation challenges, sample handling requirements, and integration points with clinical workflows.

Technology platforms underpin these biomarker types and shape feasibility, throughput, and interpretability. Established immunoassays such as enzyme-linked immunosorbent assay remain fundamental for protein quantification, while mass spectrometry offers high specificity for proteomic and metabolomic profiling. Next-generation sequencing has matured into a critical platform for genetic interrogation, encompassing RNA sequencing, targeted resequencing, and whole genome sequencing approaches that support both discovery and diagnostic applications. Polymerase chain reaction methods continue to provide rapid and sensitive nucleic acid detection, and imaging techniques-including computed tomography, functional near-infrared spectroscopy, magnetic resonance imaging, and positron emission tomography-supply anatomical and functional phenotyping that is often essential to contextualize molecular findings.

Applications span diagnostics, drug development, longitudinal monitoring, prognostic modeling, and basic research, each imposing different performance criteria and regulatory expectations. End users include contract research organizations that facilitate large-scale studies and assay validation, diagnostic laboratories that translate markers into clinical reports, hospitals and clinics that implement biomarkers at the point of care, pharmaceutical and biotechnology companies that employ markers to de-risk development programs, and research institutes that drive discovery and early validation. Understanding how each segmentation axis interacts is critical for realistic product roadmaps and partnership strategies, since success depends on aligning platform capabilities with the intended application and end-user environment.

A comprehensive regional synthesis of how structural, regulatory, and investment differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape biomarker development and commercialization outcomes

Regional dynamics exert a profound influence over regulatory pathways, investment flows, and adoption curves for neurological biomarkers, with distinct strengths and challenges across geographies. In the Americas, mature research infrastructures, deep venture and public funding channels, and leading clinical trial networks accelerate translational momentum. The region's concentration of specialized centers and payer-driven emphasis on demonstrable clinical utility foster rapid pilot adoption for diagnostics and companion markers, while also attracting partnerships that can scale promising technologies into multi-center studies.

The Europe, Middle East & Africa region presents a complex mosaic of regulatory regimes and healthcare delivery models that influence biomarker deployment. European markets often benefit from coordinated regulatory science initiatives and cross-border research consortia that support multi-national validation studies, whereas Middle Eastern and African markets display variable infrastructure maturity but rapidly expanding investment in precision medicine capabilities. Across the region, harmonization efforts and collaborative platforms are increasingly important to enable data sharing and to create interoperable standards for biomarker qualification.

In the Asia-Pacific region, fast-growing clinical research capacity, substantial public and private investment in biotechnology, and large patient populations offer significant opportunities for scalable validation and real-world data generation. Several markets within the region are investing aggressively in local manufacturing and digital health platforms, which can accelerate deployment of decentralized biomarkers and enable innovative trial designs. Combined, these regional characteristics inform strategic choices about site selection, partnership models, and regulatory engagement to optimize evidence generation and commercialization pathways.

An incisive look at how platform leadership, strategic partnerships, regulatory engagement, and commercialization models determine competitive positioning among firms in the biomarker ecosystem

Company-level dynamics underscore a landscape where technological leadership, strategic partnerships, and platform breadth determine competitive position. Instrument manufacturers and platform providers continue to differentiate through accuracy, scalability, and integration with analytic ecosystems, while reagent and consumables suppliers focus on lot-to-lot consistency, supply chain reliability, and assay standardization. Diagnostic developers are concentrating on clinical validation and payer engagement to translate analytical performance into clinical adoption, and pharmaceutical companies are increasingly embedding biomarkers into trial design to support targeted therapies and to optimize patient selection.

Strategic collaborations between industry, academic centers, and clinical networks are a recurrent theme, enabling shared access to biobanks, longitudinal cohorts, and validated endpoints. Some firms are pursuing vertical integration to control critical points in the value chain, whereas others prioritize open platforms and data interoperability to accelerate partner uptake. Across the ecosystem, competitive differentiation is achieved by investing in regulatory science to de-risk approval pathways, building robust real-world evidence programs that demonstrate clinical utility, and deploying commercial models that align diagnostic reimbursement with demonstrated health outcomes. These company-level strategies collectively influence who captures value as biomarkers transition from research tools into routine clinical applications.

Clear and practical recommendations for leaders to build supply resilience, accelerate validation, engage regulators early, and commercialize biomarkers with sustainable business models

Industry leaders should adopt a multifaceted strategy that balances near-term operational resilience with long-term technological leadership. First, strengthening supply chain resilience through supplier diversification, localized manufacturing partnerships, and longer-term procurement contracts reduces exposure to trade disruptions and cost volatility. Second, investing in analytic infrastructure and curated longitudinal datasets enhances the ability to validate biomarkers across heterogeneous populations and supports payer conversations about clinical utility and value.

Leaders should also prioritize regulatory engagement early in development to align evidentiary strategies with qualification pathways and to expedite clinical adoption. Forging consortia for precompetitive validation and participating in standards initiatives will broaden acceptance and reduce duplication of effort. From a commercial perspective, designing flexible business models-ranging from fee-for-service validation to outcome-based reimbursement pilots-can accelerate market access while sharing development risk with payers and providers. Finally, cultivating cross-disciplinary talent that blends molecular science, imaging analytics, regulatory affairs, and health economics will be critical to translate technical innovation into durable clinical impact. Together, these steps form an actionable roadmap for converting scientific advances into scalable clinical solutions and sustainable business outcomes.

A transparent mixed-methods research methodology combining systematic secondary review, expert primary interviews, and rigorous data triangulation to ensure robust and verifiable insights

The research approach combines systematic secondary review, primary stakeholder engagement, and iterative evidence synthesis to ensure balanced and verifiable insights. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, technical white papers, and industry disclosures to map technology capabilities, validation frameworks, and clinical integration models. Primary research included structured interviews with key opinion leaders, laboratory directors, clinical trial coordinators, and supply chain executives to capture real-world constraints, adoption drivers, and operational trade-offs.

Data triangulation was used to reconcile findings across sources and to highlight consensus versus divergence on critical issues such as assay standardization, regulatory pathways, and commercialization barriers. Quality control procedures included double-blind verification of interview transcripts, cross-referencing of technical specifications, and validation of analytic assumptions with independent domain experts. Limitations of the methodology relate to variability in publicly available data for emerging biomarkers and differential reporting across regions; where gaps existed, qualitative expert judgment was used and transparently annotated. This mixed-methods design prioritizes reproducibility and traceability while capturing the nuanced perspectives necessary for actionable decision-making.

A conclusive synthesis emphasizing where scientific advances, operational resilience, and collaborative validation converge to enable clinical adoption and strategic value creation

The cumulative examination of neurological biomarkers reveals an ecosystem in transition: technological innovation, regulatory evolution, and shifting commercial incentives are collectively enabling more precise diagnostic and therapeutic strategies. Translational progress is strongest where high-fidelity measurement platforms intersect with robust analytic frameworks and collaborative evidence-generation models, producing biomarkers that can be confidently used for patient selection, monitoring, and prognostication. At the same time, practical impediments such as supply chain fragility, heterogeneity in validation standards, and regional regulatory complexity continue to shape adoption timelines and strategic choices.

Organizations that prioritize interoperability, invest in validation across diverse cohorts, and build resilient operational models will be well-positioned to convert biomarker promise into measurable clinical and commercial outcomes. By aligning product development with payer needs, engaging regulators proactively, and fostering strategic partnerships, stakeholders can realize the full potential of biomarkers to improve patient care and to de-risk therapeutic development. The conclusion reinforces the need for deliberate, collaborative, and well-resourced approaches to translate scientific advances into routine clinical practice.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of plasma phosphorylated tau 217 assays for early Alzheimer's detection in multicenter clinical studies
• 5.2. Emergence of ultrasensitive single-molecule array technology for quantifying neurofilament light chain levels in blood samples
• 5.3. Development of multiplex cerebrospinal fluid biomarker panels combining amyloid beta and tau isoforms for differential dementia diagnosis
• 5.4. Adoption of digital immunoassay platforms enabling remote monitoring of biomarker fluctuations in Parkinson's disease patients
• 5.5. Expansion of artificial intelligence algorithms to interpret complex biomarker data patterns in early detection of neurodegenerative disorders
• 5.6. Advancements in blood-based inflammatory biomarker assays to track microglial activation in multiple sclerosis therapeutic trials
• 5.7. Growth of regulatory support pathways for novel neurological biomarker clearance in drug development and personalized medicine applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurological Biomarkers Market, by Biomarker Type

• 8.1. Cellular
• 8.2. Genetic
• 8.3. Imaging
• 8.4. Metabolite
• 8.5. Protein

9. Neurological Biomarkers Market, by Technology Platform

• 9.1. Enzyme-Linked Immunosorbent Assay
• 9.2. Imaging Techniques
  • 9.2.1. Computed Tomography
  • 9.2.2. Functional Near-Infrared Spectroscopy
  • 9.2.3. Magnetic Resonance Imaging
  • 9.2.4. Positron Emission Tomography
• 9.3. Mass Spectrometry
• 9.4. Next-Generation Sequencing
  • 9.4.1. RNA Sequencing
  • 9.4.2. Targeted Resequencing
  • 9.4.3. Whole Genome Sequencing
• 9.5. Polymerase Chain Reaction

10. Neurological Biomarkers Market, by Application

• 10.1. Diagnostics
• 10.2. Drug Development
• 10.3. Monitoring
• 10.4. Prognostics
• 10.5. Research

11. Neurological Biomarkers Market, by End User

• 11.1. Contract Research Organizations
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals & Clinics
• 11.4. Pharmaceutical & Biotechnology Companies
• 11.5. Research Institutes

12. Neurological Biomarkers Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Neurological Biomarkers Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Neurological Biomarkers Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Danaher Corporation
  • 15.3.2. Thermo Fisher Scientific Inc.
  • 15.3.3. Roche Holding AG
  • 15.3.4. Siemens Healthineers AG
  • 15.3.5. Abbott Laboratories
  • 15.3.6. Bio-Rad Laboratories, Inc.
  • 15.3.7. PerkinElmer, Inc.
  • 15.3.8. Quanterix Corporation
  • 15.3.9. Meso Scale Diagnostics, LLC
  • 15.3.10. Fujirebio Diagnostics, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 183. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 185. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 198. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 199. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 200. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 201. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 202. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 203. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 204. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 212. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 213. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 214. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 215. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 216. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 217. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 218. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 219. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 220. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 258. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 260. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 262. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 263. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 275. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 276. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 277. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN NEUROLOGICAL